Vivani Medical, Inc. (VANI) awards stock options in lieu of director fees

Q: What stock option grant did Daniel Bradbury report for Vivani Medical (VANI)?

Director Daniel Bradbury reported receiving 7,965 non-qualified stock options to buy Vivani Medical common stock at 1.3000 per share. The options are held directly and represent his reported position from this specific grant.

Q: What are the key terms of Daniel Bradbury’s Vivani Medical (VANI) stock options?

Bradbury’s options cover 7,965 shares of common stock at an exercise price of 1.3000 per share. They have a 10-year term , expiring on July 26, 2026 , and are structured as non-qualified stock options.

Q: How do the Vivani Medical (VANI) options granted to Daniel Bradbury vest?

The stock options granted to Bradbury vest quarterly through December 31, 2026 , contingent on his continued service with Vivani Medical. This means additional portions of the grant become exercisable at the end of each quarter until that date.

Q: Why were these Vivani Medical (VANI) options awarded to Daniel Bradbury?

The options were awarded under Vivani Medical’s non-employee director compensation policy in lieu of $8,000 in cash retainer fees. The award was provided as consideration for Bradbury’s increased committee service on the company’s board.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BRADBURY DANIEL reported acquisition or exercise transactions in this Form 4 filing.

Vivani Medical, Inc. reported that director Daniel Bradbury received a grant of 7,965 non-qualified stock options to buy common stock at 1.3000 per share. The options have a 10-year term, expire on July 26, 2026, and vest quarterly through December 31, 2026, subject to his continued service. The award, held directly, was issued under the non-employee director compensation policy in lieu of $8,000 in cash retainer fees for increased committee service, leaving him with 7,965 options reported in this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BRADBURY DANIEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy) ^{F2, F1}	7,965	$1.30	$10K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 7,965 shares (Direct)

Footnotes (2)

F1. The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date.
F2. Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service.

Key Figures

Options granted: 7,965.0000 shares Exercise price: 1.3000 per share Underlying common shares: 7,965.0000 shares +3 more

6 metrics

Options granted 7,965.0000 shares Non-qualified stock options granted to director Daniel Bradbury

Exercise price 1.3000 per share Conversion or exercise price for the options

Underlying common shares 7,965.0000 shares Vivani Medical common stock underlying the non-qualified options

Expiration date 2026-07-26 Expiration of the option term for this grant

Cash fees replaced $8,000 Cash retainer fees replaced by the option award

Vesting end date December 31, 2026 Final date through which the options vest quarterly

Key Terms

Non-Qualified Stock Option (right to buy), non-employee director compensation policy, cash retainer fees, vests quarterly

4 terms

Non-Qualified Stock Option (right to buy) financial

"security_title shows a Non-Qualified Stock Option (right to buy)"

non-employee director compensation policy financial

"Awarded pursuant to the Issuer's non-employee director compensation policy"

cash retainer fees financial

"Awarded in lieu of cash retainer fees of $8,000"

vests quarterly financial

"The stock options have a 10-year term and vests quarterly through December 31, 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 06:48 PM Accepted by SEC EDGAR 07/28/2026 - 06:48 PM

FAQ

What stock option grant did Daniel Bradbury report for Vivani Medical (VANI)?

Director Daniel Bradbury reported receiving 7,965 non-qualified stock options to buy Vivani Medical common stock at 1.3000 per share. The options are held directly and represent his reported position from this specific grant.

What are the key terms of Daniel Bradbury’s Vivani Medical (VANI) stock options?

Bradbury’s options cover 7,965 shares of common stock at an exercise price of 1.3000 per share. They have a 10-year term, expiring on July 26, 2026, and are structured as non-qualified stock options.

How do the Vivani Medical (VANI) options granted to Daniel Bradbury vest?

The stock options granted to Bradbury vest quarterly through December 31, 2026, contingent on his continued service with Vivani Medical. This means additional portions of the grant become exercisable at the end of each quarter until that date.

Why were these Vivani Medical (VANI) options awarded to Daniel Bradbury?

The options were awarded under Vivani Medical’s non-employee director compensation policy in lieu of $8,000 in cash retainer fees. The award was provided as consideration for Bradbury’s increased committee service on the company’s board.

How many Vivani Medical (VANI) options does Daniel Bradbury hold after this reported grant?

Following this reported transaction, Bradbury is shown holding 7,965 non-qualified stock options directly. These options are all tied to this grant and relate to underlying Vivani Medical common shares as disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRADBURY DANIEL

(Last)

(First)

(Middle)

C/O VIVANI MEDICAL, INC.

1350 S. LOOP ROAD

(Street)

ALAMEDA

CALIFORNIA

94502

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$1.3	07/27/2026		A		7,965		⁽¹⁾	07/26/2026	Common Stock	7,965	$1.3⁽²⁾	7,965⁽²⁾	D

Explanation of Responses:

1. The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date.

2. Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service.

	/s/ Anthony Baldor, Attorney-in-fact	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR